What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year

Krensavage Asset Management bought 241,245 Ultragenyx shares last quarter, ending with 390,879 shares valued at $8.19 million, up $4.75 million in quarter-end value. The stake now represents 3.2% of fund AUM, suggesting a notable but not aggressive conviction increase. The article frames the purchase against improving revenue trends, 2026 pipeline catalysts, and a restructuring plan aimed at profitability in 2027.

Analysis

This is less a sentiment signal on RARE and more a read-through on what biotech specialists are willing to underwrite ahead of a catalyst-rich 12-month window. Krensavage’s added weight alongside UTHR/EXEL/BMRN suggests the fund is rotating toward companies with visible commercial assets plus near-term pipeline de-risking, which should keep relative-support bids under better-quality rare-disease names even if the broader biotech tape stays choppy. The second-order effect is that capital may continue to migrate away from cash-burning platform stories toward late-stage orphan-drug names with a clearer path to self-funding.

The key risk is that the market is already pricing in the “turning point” narrative too early: if 2026 readouts slip or are mixed, RARE can re-rate violently because expectations are anchored to profitability by 2027. With a roughly $2.4B equity value against negative TTM earnings, this is a duration-sensitive setup; any delay in launches or cost takeout translates into multiple compression, not just EPS cuts. The next 1-2 quarters matter more for positioning than the long-term story, because the stock likely trades on confirmation of pipeline execution rather than revenue growth alone.

The contrarian view is that the easy part of the commercial ramp may already be largely known, while the hard part is converting pipeline optionality into durable value without additional dilution or setbacks. If management executes on expense reduction, the market may finally start valuing RARE on a probability-weighted cash flow path rather than a binary biotech discount. But if 2026 catalysts fail to expand addressable market meaningfully, the current bounce risk is vulnerable to a “good company, mediocre stock” outcome.

Key Decisions for Investors

• Long RARE on a staged basis into catalyst windows over the next 3-6 months; best risk/reward is buying weakness below current levels with a 12-month view, targeting a re-rating if pipeline data validate the 2027 profitability path.
• Pair trade: long RARE / short a higher-beta, less visible biotech with no near-term de-risking; this expresses preference for names with commercial revenue plus operating leverage while limiting sector beta.
• Sell out-of-the-money RARE calls against a starter long if implied volatility spikes ahead of data/approval events; this monetizes catalyst premium while keeping upside exposure to a successful readout.
• For event-driven accounts, buy limited-risk call spreads in RARE 6-9 months out; the setup is asymmetric only if at least one major catalyst lands cleanly, but downside is capped if timelines slip.
• Overweight UTHR relative to RARE in a quality-biotech basket; Krensavage’s positioning implies the market is still paying for durability, and UTHR remains the cleaner compounder if RARE’s pipeline disappoints.